Coronavirus disease (COVID)‐19 is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The availability of effective vaccines has helped to reduce the risk of COVID-19. Patients with blood cancer may be at a higher risk of COVID-19 infection because of impaired immunity secondary to their disease and/or treatment.
This webinar will address evidence and recommendations on vaccination in this vulnerable group of patients. The question of vaccination in bleeding and clotting disorders including in patients who are on antiplatelet or anticoagulant drugs can be perplexing, and will also be discussed.
About the speaker
Associate Professor Dr Dipti Talaulikar is a Senior Staff Specialist in Clinical and Laboratory Haematology at Canberra Hospital. Her clinical and research interest in malignant haematology including Non-Hodgkin Lymphoma, Myeloma and Myeloproliferative Neoplasms has resulted in numerous publications. Her expertise ranges across Translational and Clinical Research, Genomics and Medical Education.
She is an Associate Professor at the Australian National University, chair of the Specialist Working Group (Haematology) at the National Blood Authority, a long-standing member of Myeloma Australia’s Medical and Scientific Advisor Group, and member of other leading cancer trial and research groups in Australia.
Dr. Talaulikar contributes to medical workforce development and advocacy for equity of access to diagnostic tests and blood cancer treatments through leadership roles in organizations such as Royal College of Pathologists of Australasia (RCPA), National Blood Authority and Myeloma Australia. She is recognized as a key opinion leader (KOL) and is regularly invited to participate in Advisory Boards to provide guidance into clinical development of drugs, feedback into trial protocols and insights into research opportunities. She has authored both national and international clinical practice guidelines that have had a significant impact on cancer patient care.